| Post | Subject | | |
|
#131
|
Knocking out genes that express IL-1R1, .... in
|
NY1972
| 05/18/22 09:35:32 PM |
|
#130
|
I do think CAR-T's will have a role
|
jondoeuk
| 05/18/22 01:24:23 PM |
|
#129
|
Sounds like the second for up to five
|
jondoeuk
| 05/18/22 01:18:04 PM |
|
#128
|
How about inserting MMR gene into MSI cancers
|
NY1972
| 05/16/22 06:04:53 PM |
|
#127
|
If DTIL can unsteath cancer cells before treating
|
NY1972
| 05/16/22 10:51:26 AM |
|
#126
|
ADXS called that HOT. It turned out to
|
NY1972
| 05/16/22 10:20:42 AM |
|
#125
|
It is 'personalised' in a sense. ADAP will
|
jondoeuk
| 05/15/22 09:13:06 PM |
|
#124
|
Is 'personalized allogeneic' oxymoron?
|
NY1972
| 05/15/22 08:49:45 PM |
|
#123
|
I do think they should focus on their
|
jondoeuk
| 05/15/22 01:16:38 PM |
|
#122
|
I agree. RHHBY's Genentech signed a deal with
|
jondoeuk
| 05/15/22 01:03:07 PM |
|
#121
|
Cell therapy will be the backbone of therapies
|
NY1972
| 05/14/22 09:26:23 PM |
|
#120
|
NVS should buy DTIL with their stockpile of peanuts.
|
NY1972
| 05/12/22 04:13:13 PM |
|
#119
|
New YTB323 data https://library.ehaweb.org/eha/2022/eha2022-congress/357076/mich
|
jondoeuk
| 05/12/22 02:37:39 PM |
|
#118
|
NVS claimed to deliver 10-50 fold few CART
|
NY1972
| 05/10/22 08:13:33 PM |
|
#117
|
Is NVS picking CD39-CD69- t cells?
|
jondoeuk
| 05/10/22 06:50:46 PM |
|
#116
|
Is NVS picking CD39-CD69- t cells? Which alloc
|
NY1972
| 05/10/22 11:36:06 AM |
|
#115
|
ARCUS is safe relatively speaking.
|
NY1972
| 05/09/22 11:28:48 AM |
|
#114
|
Hi NY1972, ARCUS is superior in soooo
|
MI Dendream
| 05/08/22 11:45:02 PM |
|
#113
|
Ticking time bomb? monitoring patients undergoing CRISPR-Cas9-based editing
|
NY1972
| 05/07/22 07:08:39 PM |
|
#112
|
Too many biotechs were fat pigs destined for
|
NY1972
| 05/06/22 06:39:51 PM |
|
#111
|
T-charge must be a magical hotel for the
|
NY1972
| 05/06/22 06:31:48 PM |
|
#110
|
Nothing I could fine. Q1 financials are on Monday.
|
jondoeuk
| 05/06/22 04:20:24 PM |
|
#109
|
It seems that instead of the current activation
|
jondoeuk
| 05/06/22 04:18:06 PM |
|
#108
|
No bad news after 12% sell down?
|
NY1972
| 05/05/22 10:29:46 PM |
|
#107
|
If LD conditioning is part of the treatment,
|
NY1972
| 05/03/22 10:49:42 PM |
|
#106
|
No, but it is used. Either fludarabine (30
|
jondoeuk
| 05/03/22 05:12:49 PM |
|
#105
|
No LD mentioned in YTB323 P1 protocol
|
NY1972
| 05/03/22 05:06:59 PM |
|
#104
|
YTB323 (anti-CD19) is being tested in patients with
|
jondoeuk
| 05/03/22 04:16:35 PM |
|
#103
|
PBCAR0191 with eLD will be targeting AUTO CART
|
NY1972
| 05/02/22 09:20:07 PM |
|
#102
|
CART T as 1st line treatment without LD?
|
NY1972
| 05/02/22 09:05:31 PM |
|
#101
|
Based on the data so far, PBCAR0191 with
|
jondoeuk
| 05/02/22 08:49:38 PM |
|
#100
|
Clinical data https://www.globenewswire.com/news-release/2021/12/13/2351117/0/en
|
jondoeuk
| 05/02/22 08:35:13 PM |
|
#99
|
NVS CART T needs a charge soon. Selling
|
NY1972
| 05/02/22 02:20:44 PM |
|
#98
|
If CMO can deliver 80% ORR with 50%
|
NY1972
| 05/02/22 01:31:07 PM |
|
#97
|
Yes, but I think they need to be
|
jondoeuk
| 05/02/22 12:16:39 PM |
|
#96
|
VX-880 is an allo (stem cell-derived), insulin-producing islet
|
jondoeuk
| 05/02/22 12:12:57 PM |
|
#95
|
No immunosuppressive regimen needed for in vivo edit
|
NY1972
| 05/02/22 11:20:00 AM |
|
#94
|
I will be interested to hear how many
|
NY1972
| 05/01/22 10:18:14 PM |
|
#93
|
No, but I doubt the market will view
|
jondoeuk
| 05/01/22 08:27:29 PM |
|
#92
|
FT596, not working for DLBCL
|
NY1972
| 04/30/22 11:14:29 PM |
|
#91
|
FT516-101: Interim Phase 1 Clinical Data in R/R
|
NY1972
| 04/30/22 10:53:05 PM |
|
#90
|
Inserting beta-2 microglobulin gene into tumor cells with
|
NY1972
| 04/30/22 02:45:40 PM |
|
#89
|
DTIL mgt. should cut burn to allow in
|
NY1972
| 04/29/22 10:26:19 PM |
|
#88
|
I guess you are expecting bad news.
|
NY1972
| 04/29/22 07:25:03 PM |
|
#87
|
Well, I won't be buying, as there is
|
jondoeuk
| 04/29/22 07:11:38 PM |
|
#86
|
PBCAR0191 in Patients With r/r NHL and r/r
|
NY1972
| 04/28/22 03:27:56 PM |
|
#85
|
DTIL is a bargain?
|
NY1972
| 04/28/22 10:40:56 AM |
|
#84
|
Another https://www.fiercebiotech.com/research/designing-better-car-t-cell-thera
|
jondoeuk
| 04/02/22 08:24:47 PM |
|
#83
|
I have found some the other knockouts, which
|
jondoeuk
| 03/30/22 06:30:07 PM |
|
#82
|
Well, if it has been designed to overcome
|
jondoeuk
| 03/30/22 06:24:13 PM |
| Post | Subject | | |